As JAK2 is pharmaceutically relatively easy to target (e.g. the pan-JAK inhibitor tofacitinib is already routinely used for the treatment of inflammatory and neoplastic diseases [21]), these results strongly argue for clinical studies into the potential of JAK inhibitors to combat clinical chemoresistance in breast cancer. The gene discussed is JAK2; the disease is neoplasm.